SEC Form 4	
------------	--

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										

Estimated average burden	
hours per response:	0.5

MANGANO ROSS J			2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [BPAX] 3. Date of Earliest Transaction (Month/Day/Year) 12/19/2007		tionship of Reporting Persor all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)
(Street) SOUTH BEND (City)	IN (State)	46634 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing ((Form filed by One Reporti Form filed by More than C Person	ing Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	12/19/2007		Р		50,000	A	\$3.694	1,663,149	Ι	By JO & Co.	
Common Stock								30,000	I	See footnote ⁽¹⁾	
Common Stock								70,756	D		
Common Stock								48,333	Ι	By Trust ⁽²⁾	
Common Stock								33,333	Ι	By Trust ⁽²⁾	
Common Stock								33,333	Ι	By Trust ⁽²⁾	
Common Stock								100,000	I	See footnote ⁽³⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		on Date Amount of		bunt of urities Derivative Security derivative Securities ivertige Instr. 5) Beneficially vivative Owned Owned urity (Instr. 3 Following 4) Reported		derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares are held by Oliver & Co., of which Mr. Mangano is a trustee.

2. Shares are held indirectly by Mr. Mangano in various trusts of which Mr. Mangano is the trustee.

3. Shares are held indirectly by Mr. Mangano as an investment advisor on behalf of an individual.

<u>/s/ Phillip B. Donenberg,</u> <u>attorney-in-fact</u>

12/19/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.